Venetoclax has been extensively investigated across hundreds of clinical trials spanning Phase 1 through Phase 4 evaluations for various hematologic malignancies. Clinical research primarily focuses on acute myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndromes, and plasma cell myeloma, both as monotherapy and in novel combination regimens. These studies assess therapeutic efficacy, minimal residual disease clearance, and safety profiles in both frontline and relapsed or refractory patient populations.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02689440 | ACTIVE_NOT_RECRUITING | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia |
M.D. Anderson Cancer Center |
2016-02-19 | PHASE2 |
| NCT05725200 | RECRUITING | Metastatic Colorectal Cancer |
Oslo University Hospital |
2022-09-27 | PHASE2 |
| NCT07437950 | RECRUITING | Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2027-04-18 | PHASE2 |
| NCT03013998 | RECRUITING | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia |
Beat AML, LLC |
2016-11 | PHASE2; PHASE3 |
| NCT05947851 | RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL |
Merck Sharp & Dohme LLC |
2023-08-08 | PHASE3 |
| NCT07294677 | RECRUITING | Leukemia; Lymphoma |
University of Chicago |
2026-03-17 | PHASE1; PHASE2 |
| NCT07007312 | RECRUITING | Acute Myeloid Leukemia (AML) |
Kura Oncology, Inc. |
2025-09-26 | PHASE3 |
| NCT07604233 | NOT_YET_RECRUITING | Myeloid Leukemia |
M.D. Anderson Cancer Center |
2026-11-30 | PHASE1; PHASE2 |
| NCT05753501 | ACTIVE_NOT_RECRUITING | Hematologic Cancer |
AbbVie |
2023-06-09 | PHASE1 |
| NCT05091424 | RECRUITING | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Hoffmann-La Roche |
2022-03-07 | PHASE1 |
| NCT02966756 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
AbbVie |
2017-10-12 | PHASE2 |
| NCT04062266 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia in Remission; FLT3 Gene Mutation; Hematologic and Lymphocytic Disorder; Acute Myeloid Leukemia; Minimal Residual Disease Persistence; Therapy-Related Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2019-09-13 | PHASE2 |
| NCT06454409 | SUSPENDED | Myelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
City of Hope Medical Center |
2025-05-21 | PHASE1 |
| NCT07082452 | NOT_YET_RECRUITING | Leukemia, B-Cell, Chronic; Leukemia |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-09 | PHASE3 |
| NCT05904106 | RECRUITING | Acute Myeloid Leukemia |
Technische Universität Dresden |
2024-04-07 | PHASE2 |
| NCT07713732 | NOT_YET_RECRUITING | Small Cell Lung Cancer ( SCLC ); Neuroendocrine Cancer; Malignant Pleural Mesotheliomas (Mpm); Synovial Sarcomas |
Treeline Biosciences, Inc. |
2026-07-25 | PHASE1 |
| NCT05442216 | RECRUITING | Acute Myeloid Leukemia |
Joshua Zeidner |
2024-05-01 | PHASE2 |
| NCT07320235 | RECRUITING | Relapsed Acute Myeloid Leukemia |
Douglas Tremblay |
2026-01-02 | PHASE1 |
| NCT07672262 | RECRUITING | Acute Myeloid Leukemia; Intermediate Risk Acute Myeloid Leukemia; Consolidation Therapy |
The First Affiliated Hospital of Soochow University |
2026-06-01 | PHASE2 |
| NCT07238686 | RECRUITING | Myelodysplastic Syndromes |
Beijing 302 Hospital |
2025-06-20 | PHASE2 |
| NCT07078591 | RECRUITING | Acute Myeloid Leukemia |
Beijing 302 Hospital |
2025-06-20 | PHASE2 |
| NCT06855810 | RECRUITING | Acute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-03-11 | PHASE2; PHASE3 |
| NCT07153497 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2026-05-27 | PHASE2 |
| NCT05735184 | RECRUITING | Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML; AML With Mutated NPM1; Acute Myeloid Leukemia Recurrent; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation; KMT2Ar; Myeloid Sarcoma; Nucleophosmin 1-mutated Acute Myeloid Leukemia |
Kura Oncology, Inc. |
2023-07-18 | PHASE1 |
| NCT06972641 | RECRUITING | AML; MDS |
Ruijin Hospital |
2025-06-10 | PHASE2; PHASE3 |
| NCT07396480 | RECRUITING | Venentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Acute Myeloid Leucemia; Myeldysplastic Syndrome (MDS) |
First Affiliated Hospital of Zhejiang University |
2026-03-01 | PHASE3 |
| NCT06764238 | RECRUITING | Acute Lymphoblastic Leukemia ALL; Childhood Leukemia, Acute Lymphoblastic; B Cell Acute Lymphoblastic Leukemia (B-ALL) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-03 | PHASE2; PHASE3 |
| NCT06561074 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; T-Cell Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2025-09-25 | PHASE2 |
| NCT07513129 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; Lymphoma |
M.D. Anderson Cancer Center |
2026-06-05 | PHASE1 |
| NCT07738887 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
The Lymphoma Academic Research Organisation |
2026-12-31 | PHASE2 |
| NCT05910801 | RECRUITING | Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma |
Academic and Community Cancer Research United |
2024-01-04 | PHASE2 |
| NCT06652438 | RECRUITING | Acute Myeloid Leukemia, Adult |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2025-05-05 | PHASE3 |
| NCT07690891 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia |
Medical College of Wisconsin |
2026-10-01 | PHASE2 |
| NCT07154264 | RECRUITING | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Dizal Pharmaceuticals |
2025-09-22 | PHASE2 |
| NCT07755202 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; AML With FLT3 Mutation |
Florian Kuchenbauer |
2026-09-01 | PHASE2 |
| NCT06471946 | RECRUITING | Higher-risk Myelodysplastic Syndromes |
Navy General Hospital, Beijing |
2024-10-01 | PHASE1; PHASE2 |
| NCT07691047 | NOT_YET_RECRUITING | Chronic Lymphoid Leukemia |
Private Hospital of Confluent, France |
2026-07-31 | |
| NCT07719556 | RECRUITING | Mantle Cell Lymphoma (MCL) |
The First Affiliated Hospital with Nanjing Medical University |
2026-07-15 | PHASE2 |
| NCT07563179 | RECRUITING | Acute Myeloid Leukemia; Relapse/Recurrence |
Shenzhen University General Hospital |
2026-04-21 | PHASE2 |
| NCT07218510 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
City of Hope Medical Center |
2026-01-07 | PHASE2 |
| NCT07521124 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) in Remission |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2026-06-01 | |
| NCT07766850 | NOT_YET_RECRUITING | R/R AML |
Christer C Nilsson |
2026-10 | PHASE1; PHASE2 |
| NCT07014462 | ENROLLING_BY_INVITATION | AML - Acute Myeloid Leukemia |
University of Vermont |
2025-09-01 | PHASE1 |
| NCT07635485 | NOT_YET_RECRUITING | Hypoplastic Acute Myeloid Leukemia; Secondary AML (Adult) |
The First Affiliated Hospital of Soochow University |
2026-06-01 | |
| NCT06317649 | RECRUITING | Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2024-09-27 | PHASE2 |
| NCT07024706 | RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
AstraZeneca |
2026-06-04 | PHASE2 |
| NCT07023588 | RECRUITING | Acute Myeloid Leukemia (AML) |
Yehui Tan |
2025-06-01 | PHASE2 |
| NCT06696183 | RECRUITING | AML - Acute Myeloid Leukemia |
Technische Universität Dresden |
2025-04-25 | PHASE2 |
| NCT06782542 | RECRUITING | Acute Myeloid Leukemia; IDH1 Mutation |
Justin Watts, MD |
2026-03-31 | PHASE2 |
| NCT05791409 | RECRUITING | CLL/SLL |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-04-10 | PHASE1; PHASE2 |
| NCT04628026 | RECRUITING | Acute Myeloid Leukemia |
University of Ulm |
2022-09-13 | PHASE3 |
| NCT07423104 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
University of Rochester |
2026-08-15 | PHASE2 |
| NCT05486481 | WITHDRAWN | AL Amyloidosis; Light Chain (AL) Amyloidosis; Systemic Light Chain Disease |
Alfred Chung, MD |
2024-01-08 | PHASE1; PHASE2 |
| NCT07177079 | RECRUITING | Acute Myeloid Leukemia |
Kittika Poonsombudlert |
2026-03-18 | PHASE1 |
| NCT06191978 | RECRUITING | Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2024-03-07 | PHASE1 |
| NCT06448013 | RECRUITING | Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2025-03-07 | PHASE1 |
| NCT07007052 | RECRUITING | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
French Innovative Leukemia Organisation |
2025-12-11 | PHASE2 |
| NCT07358195 | NOT_YET_RECRUITING | Kidney Failure Chronic; Stem Cell Transplant; Stem Cell Transplant Complications; Tolerance; Hematologic Cancer |
Massachusetts General Hospital |
2026-07 | EARLY_PHASE1 |
| NCT07075016 | RECRUITING | Acute Myeloid Leukemia |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2025-08-05 | PHASE3 |
| NCT05342584 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Montefiore Medical Center |
2022-05-25 | PHASE1 |
| NCT06557421 | RECRUITING | Acute Myeloid Leukemia |
Institut Paoli-Calmettes |
2026-02-04 | PHASE2 |
| NCT04269902 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
National Cancer Institute (NCI) |
2021-03-02 | PHASE3 |
| NCT06644183 | RECRUITING | Leukemia; Relapsed Leukemia; Chronic Lymphocytic Leukemia; Relapsed Cancer; Refractory Leukemia |
Jennifer R. Brown, MD, PhD |
2025-03-19 | PHASE1; PHASE2 |
| NCT07059975 | RECRUITING | Acute Myeloid Leukemia; Pediatric AML |
Baylor College of Medicine |
2025-10-22 | EARLY_PHASE1 |
| NCT04140487 | RECRUITING | Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic/Myeloproliferative Neoplasm |
M.D. Anderson Cancer Center |
2019-12-17 | PHASE1; PHASE2 |
| NCT07679334 | NOT_YET_RECRUITING | Myeloproliferative Neoplasm |
Roswell Park Cancer Institute |
2026-09-01 | PHASE1 |
| NCT07735117 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS) |
Ruijin Hospital |
2026-07-30 | PHASE3 |
| NCT07392814 | NOT_YET_RECRUITING | Leukemia Acute Myeloid - AML |
Nantes University Hospital |
2026-03-10 | PHASE1 |
| NCT04169737 | RECRUITING | Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2020-07-29 | PHASE2 |
| NCT07387471 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma |
AbbVie |
2026-03-17 | PHASE2 |
| NCT04847453 | ACTIVE_NOT_RECRUITING | Recurrent AL Amyloidosis; Refractory AL Amyloidosis |
National Cancer Institute (NCI) |
2022-08-03 | PHASE1 |
| NCT07642453 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
Hematology department of the 920th hospital |
2026-06-01 | PHASE2 |
| NCT05404906 | RECRUITING | Acute Myeloid Leukemia (AML) in Remission |
The First Affiliated Hospital of Soochow University |
2022-06-25 | PHASE2; PHASE3 |
| NCT06668558 | RECRUITING | Acute Myeloid Leukemia |
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias |
2024-12-16 | PHASE2 |
| NCT07643103 | NOT_YET_RECRUITING | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) |
Institute of Hematology & Blood Diseases Hospital, China |
2026-06-12 | PHASE2 |
| NCT04543916 | WITHDRAWN | Relapsed Small Cell Lung Cancer; Refractory Small Cell Lung Carcinoma |
Virginia Commonwealth University |
2021-06-30 | PHASE1; PHASE2 |
| NCT06846671 | RECRUITING | CLL; Chronic Lymphocytic Leukemia |
BeOne Medicines |
2025-04-10 | PHASE3 |
| NCT06954987 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2026-07-17 | PHASE2 |
| NCT07091006 | NOT_YET_RECRUITING | Relapse Leukemia |
Ruijin Hospital |
2025-08-01 | PHASE2 |
| NCT07283094 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
Montefiore Medical Center |
2026-02-03 | PHASE1 |
| NCT06558604 | RECRUITING | Lymphoma, Mantle-Cell |
The Lymphoma Academic Research Organisation |
2025-02-21 | PHASE2 |
| NCT05197192 | RECRUITING | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2022-04-19 | PHASE3 |
| NCT07231952 | RECRUITING | Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma |
Memorial Sloan Kettering Cancer Center |
2025-11-11 | PHASE2 |
| NCT03984448 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double-Expressor Lymphoma; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
National Cancer Institute (NCI) |
2019-10-22 | PHASE2; PHASE3 |
| NCT07514832 | RECRUITING | AML (Acute Myeloid Leukemia) |
Beijing 302 Hospital |
2026-04-15 | PHASE2 |
| NCT07493161 | RECRUITING | Ph+ ALL |
Institute of Hematology & Blood Diseases Hospital, China |
2026-04-10 | |
| NCT07507825 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
First People's Hospital of Hangzhou |
2026-03-31 | PHASE2 |
| NCT05530421 | RECRUITING | Relapsed and Refractory Multiple Myeloma |
University of Miami |
2023-03-26 | PHASE2 |
| NCT04560322 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Massachusetts General Hospital |
2020-10-19 | PHASE2 |
| NCT07495631 | RECRUITING | Acute Lymphoblastic Leukemia, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2026-04-08 | |
| NCT06428019 | RECRUITING | Chronic Lymphocytic Leukemia |
AbbVie |
2024-08-05 | PHASE3 |
| NCT06014489 | RECRUITING | AML, Adult |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-01-17 | PHASE2 |
| NCT06456463 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Stemline Therapeutics, Inc. |
2025-01-14 | PHASE2 |
| NCT03946878 | ACTIVE_NOT_RECRUITING | Blastoid Variant Mantle Cell Lymphoma; CCND1 Protein Overexpression; CD20 Positive; CD5 Positive; FCER2 Negative; Pleomorphic Variant Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; t(11;14)(q13;q32) |
M.D. Anderson Cancer Center |
2019-08-13 | PHASE2 |
| NCT03661307 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2018-10-31 | PHASE1; PHASE2 |
| NCT07243483 | RECRUITING | Acute Myeloid Leukemia |
Centre Leon Berard |
2026-01-21 | |
| NCT07392242 | RECRUITING | Acute Myeloid Leukemia |
Memorial Sloan Kettering Cancer Center |
2026-01-27 | PHASE2 |
| NCT06621199 | RECRUITING | Acute Myeloid Leukemia |
First Affiliated Hospital of Zhejiang University |
2024-07-08 | PHASE2 |
| NCT07557056 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Jennifer Woyach |
2026-09-01 | PHASE2 |
| NCT05365035 | RECRUITING | Myelodysplastic Syndromes; Myeloproliferative Chronic Myelomonocytic Leukemia |
M.D. Anderson Cancer Center |
2022-09-23 | PHASE2 |
| NCT06466395 | RECRUITING | Refractory Acute Leukemia; Relapsed Acute Leukemia; Undifferentiated Leukemia; Bi-Phenotypic Leukemia |
M.D. Anderson Cancer Center |
2025-02-18 | PHASE1 |
| NCT04708054 | RECRUITING | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2021-10-21 | PHASE2; PHASE3 |
| NCT04797767 | RECRUITING | Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; Myeloid Neoplasm; Relapsed Acute Biphenotypic Leukemia; Relapsed Acute Myeloid Leukemia; Relapsed Mixed Phenotype Acute Leukemia; Relapsed Myeloid Neoplasm; Refractory Acute Biphenotypic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myeloid Neoplasm; Recurrent Myeloid Sarcoma |
University of Washington |
2022-02-04 | PHASE1; PHASE2 |
| NCT06328179 | RECRUITING | Acute Myeloid Leukemia |
Huai'an First People's Hospital |
2022-05-24 | |
| NCT06386302 | RECRUITING | AML; Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2024-08-05 | |
| NCT06571825 | RECRUITING | Acute Myeloid Leukemia |
He Huang |
2024-07-17 | PHASE4 |
| NCT05963074 | ACTIVE_NOT_RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma |
Janssen Research & Development, LLC |
2024-05-30 | PHASE2 |
| NCT04872790 | ACTIVE_NOT_RECRUITING | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Mixed Phenotype Acute Leukemia; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Mixed Phenotype Acute Leukemia |
OHSU Knight Cancer Institute |
2022-09-02 | PHASE1 |
| NCT07304011 | RECRUITING | Acute Myeloid Leukemia |
University of California, Davis |
2025-12-17 | PHASE2 |
| NCT06958705 | RECRUITING | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) |
The First Affiliated Hospital with Nanjing Medical University |
2025-12-01 | PHASE2 |
| NCT06744556 | ACTIVE_NOT_RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-21 | PHASE2 |
| NCT02781883 | RECRUITING | Acute Myeloid Leukemia (AML) |
Bio-Path Holdings, Inc. |
2016-05 | PHASE2 |
| NCT04623541 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Treatment-naïve High Risk Chronic Lymphocytic Leukemia |
Genmab |
2020-11-25 | PHASE1; PHASE2 |
| NCT07255872 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-03 | PHASE2; PHASE3 |
| NCT04581512 | RECRUITING | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes |
Ellipses Pharma |
2020-11-02 | PHASE1; PHASE2 |
| NCT04774393 | RECRUITING | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2021-05-24 | PHASE1; PHASE2 |
| NCT03331198 | ACTIVE_NOT_RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic |
Juno Therapeutics, a Subsidiary of Celgene |
2017-11-27 | PHASE1; PHASE2 |
| NCT06917911 | RECRUITING | Core Binding Factor Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2027-02-02 | PHASE2 |
| NCT06660368 | RECRUITING | Relapsed or Refractory Acute Myeloid Leukemia (AML) |
H. Lee Moffitt Cancer Center and Research Institute |
2024-11-26 | PHASE2 |
| NCT07044687 | RECRUITING | Acute Myeloid Leukemia |
AbbVie |
2025-07-24 | PHASE4 |
| NCT06686108 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Relapse |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-10-30 | PHASE2 |
| NCT06504459 | RECRUITING | Acute Monocytic Leukemia; Acute Myeloid Leukemia |
OHSU Knight Cancer Institute |
2025-01-03 | PHASE2 |
| NCT07374029 | RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse |
David Avigan |
2026-02-12 | PHASE1 |
| NCT07632170 | NOT_YET_RECRUITING | Myeloid Tumors |
Bing Han |
2026-11-01 | |
| NCT06511882 | RECRUITING | Acute Myeloid Leukemia |
H. Lee Moffitt Cancer Center and Research Institute |
2024-11-07 | PHASE2 |
| NCT07486726 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Relapse Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia (AML) |
Shanghai Jiao Tong University School of Medicine |
2026-03-15 | PHASE1; PHASE2 |
| NCT05401097 | RECRUITING | Acute Myeloid Leukemia |
Alice Mims |
2022-09-13 | PHASE2 |
| NCT03214562 | RECRUITING | High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2017-09-26 | PHASE1; PHASE2 |
| NCT07743112 | RECRUITING | Acute Myeloid Leukemia |
Maxinovel Pty., Ltd. |
2025-09-05 | PHASE2 |
| NCT07451912 | RECRUITING | Acute Myeloid Leukemia (AML); CEBPA Mutation; Unfit, New-diagnosis AML |
The First Affiliated Hospital of Soochow University |
2025-09-15 | PHASE1; PHASE2 |
| NCT05600894 | ACTIVE_NOT_RECRUITING | Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm |
National Cancer Institute (NCI) |
2023-06-27 | PHASE2 |
| NCT06712121 | RECRUITING | T Lymphoblastic Leukemia/Lymphoma |
Seoul National University Hospital |
2025-01-30 | PHASE2 |
| NCT07132684 | RECRUITING | AML, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2025-08-31 | PHASE3 |
| NCT07183878 | RECRUITING | Acute Myeloid Leukemia; High-Risk Acute Myeloid Leukemia; Myelodysplastic Syndromes; High-Risk Myelodysplastic Syndromes |
First Affiliated Hospital of Zhejiang University |
2025-08-20 | |
| NCT07214064 | NOT_YET_RECRUITING | AML (Acute Myeloid Leukemia); MDS/AML; MDS (Myelodysplastic Syndrome) |
University Hospital Tuebingen |
2026-01 | PHASE2 |
| NCT06496308 | RECRUITING | Mantle Cell Lymphoma (MCL) |
Ruijin Hospital |
2024-07-10 | PHASE3 |
| NCT03969446 | SUSPENDED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
City of Hope Medical Center |
2020-05-04 | PHASE1 |
| NCT04227847 | RECRUITING | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
Seagen, a wholly owned subsidiary of Pfizer |
2020-08-07 | PHASE1 |
| NCT04401748 | ACTIVE_NOT_RECRUITING | Myelodysplastic Syndrome (MDS) |
AbbVie |
2020-09-10 | PHASE3 |
| NCT06090786 | NOT_YET_RECRUITING | AML, Adult; Minimal Residual Disease |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2024-07 | |
| NCT04447768 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL) |
Memorial Sloan Kettering Cancer Center |
2020-12-03 | PHASE2 |
| NCT04855695 | RECRUITING | Mantle Cell Lymphoma; Refractory Lymphoma |
Austin I Kim |
2021-07-02 | PHASE1; PHASE2 |
| NCT03041688 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2018-02-08 | PHASE1 |
| NCT06445959 | RECRUITING | Mutant IDH1 Inhibitor Olutasidenib |
M.D. Anderson Cancer Center |
2024-08-29 | PHASE1; PHASE2 |
| NCT07032727 | RECRUITING | Targeted Therapy; IDH1-Mutated Malignancies; Mutations |
M.D. Anderson Cancer Center |
2025-09-12 | PHASE2 |
| NCT05986240 | RECRUITING | AML/MDS; Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Montefiore Medical Center |
2024-05-08 | PHASE1 |
| NCT04416451 | ACTIVE_NOT_RECRUITING | Marginal Zone Lymphoma |
Memorial Sloan Kettering Cancer Center |
2021-05-04 | PHASE2 |
| NCT02899052 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2017-01-19 | PHASE2 |
| NCT04975919 | ACTIVE_NOT_RECRUITING | Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Biphenotypic Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2021-09-29 | PHASE2 |
| NCT03128879 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
M.D. Anderson Cancer Center |
2017-06-16 | PHASE2 |
| NCT06311227 | RECRUITING | Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant |
National Cancer Institute (NCI) |
2024-12-16 | PHASE2 |
| NCT04150887 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
OncoVerity, Inc. |
2019-12-23 | PHASE1 |
| NCT04419519 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Memorial Sloan Kettering Cancer Center |
2020-05-13 | PHASE2 |
| NCT05529069 | RECRUITING | Mantle Cell Lymphoma; Non Hodgkin Lymphoma; Hematologic Malignancy |
M.D. Anderson Cancer Center |
2023-01-25 | PHASE2 |
| NCT07537257 | ENROLLING_BY_INVITATION | AML (Acute Myelogenous Leukemia) |
Guangdong Second Provincial General Hospital |
2026-04-01 | PHASE2; PHASE3 |
| NCT04450173 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma |
University of California, Davis |
2021-02-24 | PHASE2 |
| NCT05554406 | RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Acute Myeloid Leukemia, Myelodysplasia-Related |
National Cancer Institute (NCI) |
2024-09-25 | PHASE2 |
| NCT03710772 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
M.D. Anderson Cancer Center |
2019-05-01 | PHASE2 |
| NCT06357182 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome/Acute Myeloid Leukemia |
OHSU Knight Cancer Institute |
2024-08-22 | PHASE1 |
| NCT06372717 | RECRUITING | Acute Myeloid Leukemia Refractory; Myelodysplastic Syndrome Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts; Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia (AML) |
Apollo Therapeutics Ltd |
2024-06-04 | PHASE1 |
| NCT05650723 | ACTIVE_NOT_RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell |
Weill Medical College of Cornell University |
2023-05-08 | PHASE2 |
| NCT05428969 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Relapsed/Refractory AML |
Faron Pharmaceuticals Ltd |
2022-06-02 | PHASE1; PHASE2 |
| NCT02846623 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2017-01-31 | PHASE2 |
| NCT05388006 | RECRUITING | Chronic Lymphocytic Leukemia; Richter Syndrome; Small Lymphocytic Lymphoma |
Mayo Clinic |
2023-01-05 | PHASE2 |
| NCT05391750 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Emory University |
2022-10-19 | PHASE1 |
| NCT04939272 | ACTIVE_NOT_RECRUITING | Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma |
City of Hope Medical Center |
2022-06-29 | PHASE1; PHASE2 |
| NCT05861050 | RECRUITING | Blastoid Variant Mantle Cell Lymphoma; Mantle Cell Lymphoma; Pleomorphic Variant Mantle Cell Lymphoma |
City of Hope Medical Center |
2023-08-10 | PHASE1; PHASE2 |
| NCT05183035 | RECRUITING | Acute Myeloid Leukemia |
PedAL BCU, LLC |
2022-10-01 | PHASE3 |
| NCT03824483 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Leukemia (SLL) |
Memorial Sloan Kettering Cancer Center |
2019-02-22 | PHASE2 |
| NCT04515238 | ACTIVE_NOT_RECRUITING | Chronic Lymphoid Leukemia |
German CLL Study Group |
2020-10-01 | PHASE2 |
| NCT03862157 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Eosinophilic Leukemia, Not Otherwise Specified; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloid Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Overt Primary Myelofibrosis; Polycythemia Vera; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Prefibrotic/Early Primary Myelofibrosis |
M.D. Anderson Cancer Center |
2019-02-27 | PHASE1; PHASE2 |
| NCT06763341 | RECRUITING | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
City of Hope Medical Center |
2025-07-30 | PHASE1 |
| NCT04801797 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Massachusetts General Hospital |
2021-05-20 | PHASE2 |
| NCT03826992 | RECRUITING | Leukemia |
Children's Hospital Medical Center, Cincinnati |
2018-12-27 | PHASE1 |
| NCT06384261 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
OncoVerity, Inc. |
2024-07-22 | PHASE2 |
| NCT04161248 | ACTIVE_NOT_RECRUITING | Lymphoma, B-Cell |
Canadian Cancer Trials Group |
2020-09-02 | EARLY_PHASE1 |
| NCT05603884 | RECRUITING | Leukemia, Myeloid, Acute; AML Stage, Adult |
The First Affiliated Hospital of Xiamen University |
2022-12-01 | PHASE2 |
| NCT07517510 | ENROLLING_BY_INVITATION | Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) |
Guangdong Second Provincial General Hospital |
2026-04-01 | PHASE2 |
| NCT06621212 | RECRUITING | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy |
First Affiliated Hospital of Zhejiang University |
2024-07-05 | PHASE2 |
| NCT03629171 | RECRUITING | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2018-10-29 | PHASE2 |
| NCT04128501 | ACTIVE_NOT_RECRUITING | Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; T Acute Lymphoblastic Leukemia; Therapy-Related Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2020-05-05 | PHASE2 |
| NCT06990321 | RECRUITING | Acute Myeloid Leukemia (AML); Elderly |
Yehui Tan |
2025-06-01 | PHASE3 |
| NCT04216524 | RECRUITING | Blastic Plasmacytoid Dendritic Cell Neoplasm |
M.D. Anderson Cancer Center |
2020-05-29 | PHASE2 |
| NCT04790045 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia |
Paolo Ghia |
2023-11-01 | PHASE4 |
| NCT06466122 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Kerry Rogers |
2024-11-07 | PHASE2 |
| NCT04588922 | RECRUITING | Hematologic Malignancies |
Sellas Life Sciences Group |
2021-05-10 | PHASE1; PHASE2 |
| NCT06471738 | RECRUITING | Ann Arbor Stage II Follicular Lymphoma; Grade 1 Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma |
Chinese PLA General Hospital |
2024-07-10 | PHASE2 |
| NCT06451861 | RECRUITING | Acute Myeloid Leukemia |
Guangdong Provincial People's Hospital |
2024-08-21 | PHASE2 |
| NCT06284486 | RECRUITING | Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2024-09-23 | PHASE1; PHASE2 |
| NCT07264010 | NOT_YET_RECRUITING | Acute Myeloid Leukaemia (AML); Measurable Residual Disease (MRD) |
Nanfang Hospital, Southern Medical University |
2025-12-01 | PHASE2; PHASE3 |
| NCT06387121 | RECRUITING | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2024-04-02 | PHASE2 |
| NCT05376111 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; Recruiting |
The First Affiliated Hospital of Soochow University |
2022-04-01 | PHASE2 |
| NCT07712848 | RECRUITING | AML (Acute Myeloid Leukemia) |
The Second Affiliated Hospital of Kunming Medical University |
2026-04-01 | PHASE3 |
| NCT06757855 | RECRUITING | CML,Blast Phase |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-26 | PHASE1; PHASE2 |
| NCT07044544 | RECRUITING | Myeloid Malignancy; Hematologic Malignancy; Acute Myeloid Leukemia; Myelodysplastic Syndromes |
University of Alabama at Birmingham |
2025-07-17 | PHASE1 |
| NCT06783790 | RECRUITING | AML (Acute Myelogenous Leukemia) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-20 | PHASE2 |
| NCT06129734 | RECRUITING | Myeloid Malignancy; Acute Myeloid Leukemia |
Benjamin Tomlinson |
2025-07-28 | PHASE1; PHASE2 |
| NCT03467867 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
Georgetown University |
2018-04-26 | PHASE2 |
| NCT05955261 | SUSPENDED | Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2023-07-25 | PHASE2 |
| NCT05597306 | RECRUITING | Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse |
Terrence J Bradley, MD |
2022-11-19 | PHASE1 |
| NCT03986034 | RECRUITING | Chronic Lymphocytic Leukemia |
National Heart, Lung, and Blood Institute (NHLBI) |
2019-06-26 | PHASE2 |
| NCT05226455 | ACTIVE_NOT_RECRUITING | MDS; AML |
Groupe Francophone des Myelodysplasies |
2022-11-23 | PHASE1; PHASE2 |
| NCT05677919 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Mayo Clinic |
2023-01-31 | PHASE2 |
| NCT06082934 | RECRUITING | Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia |
Xijing Hospital |
2023-11-01 | PHASE1; PHASE2 |
| NCT04895436 | RECRUITING | Chronic Lymphocytic Leukemia (CLL) |
AbbVie |
2022-03-28 | PHASE2 |
| NCT04746235 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2021-02-22 | PHASE2 |
| NCT00501826 | RECRUITING | T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2007-07-11 | PHASE2 |
| NCT06524375 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
Genentech, Inc. |
2024-08-09 | PHASE2 |
| NCT05453903 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
Janssen Research & Development, LLC |
2022-10-04 | PHASE1 |
| NCT07490288 | RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2026-05-08 | |
| NCT05168930 | RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Dana-Farber Cancer Institute |
2022-02-18 | PHASE2 |
| NCT05657639 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2022-10-01 | PHASE2 |
| NCT07163793 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia in Remission |
Northwell Health |
2024-10-07 | PHASE2 |
| NCT05657652 | RECRUITING | Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
2022-10-01 | |
| NCT06210750 | WITHDRAWN | T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
National Cancer Institute (NCI) |
2024-08-09 | PHASE2 |
| NCT07244367 | RECRUITING | Acute Myeloid Leukaemia (AML) |
Sohag University |
2025-09-01 | |
| NCT06237192 | RECRUITING | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
National Research Center for Hematology, Russia |
2023-04-01 | |
| NCT06156579 | RECRUITING | AML; MDS |
University Hospital Tuebingen |
2023-11-04 | PHASE2 |
| NCT04082897 | ACTIVE_NOT_RECRUITING | CLL Transformation |
Niguarda Hospital |
2019-10-04 | PHASE2 |
| NCT06337331 | WITHDRAWN | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Northside Hospital, Inc. |
2024-08-31 | PHASE2 |
| NCT05554419 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2026-07-01 | PHASE2 |
| NCT02992522 | ACTIVE_NOT_RECRUITING | B-Cell Lymphoma, Unspecified; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Transformed Recurrent Non-Hodgkin Lymphoma; B-Cell |
Beth Christian |
2017-02-21 | PHASE1 |
| NCT02392572 | TERMINATED | Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2015-11-03 | PHASE1; PHASE2 |
| NCT06554626 | RECRUITING | Precursor B-Cell Lymphoblastic Leukemia |
First Affiliated Hospital of Zhejiang University |
2024-08-15 | PHASE2 |
| NCT05211570 | RECRUITING | Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acute Myeloid Leukemia |
AB Science |
2022-06-01 | PHASE1; PHASE2 |
| NCT06536959 | RECRUITING | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Myelodysplastic Syndromes; Minimal Residual Disease |
Beijing 302 Hospital |
2024-07-18 | PHASE2 |
| NCT04501939 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
University of California, San Diego |
2020-08-06 | PHASE2 |
| NCT05069051 | ACTIVE_NOT_RECRUITING | Chronic Lymphoid Leukemia in Relapse |
University Hospital Tuebingen |
2022-01-19 | PHASE2 |
| NCT06055621 | RECRUITING | Acute Myeloid Leukemia |
Institut Paoli-Calmettes |
2024-05-22 | PHASE2 |
| NCT06483906 | RECRUITING | Acute Myeloid Leukemia |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-07-02 | PHASE2 |
| NCT06537843 | RECRUITING | Acute Myeloid Leukemia |
Hospital Municipal São José |
2023-12-01 | PHASE2 |
| NCT06742463 | RECRUITING | Acute T Lymphpblastic Leukemia/Lymphoma |
First Affiliated Hospital of Zhejiang University |
2024-12 | PHASE2 |
| NCT06810791 | RECRUITING | Newly Diagnosed Acute Myeloid Leukemia With High Risk |
Nanfang Hospital, Southern Medical University |
2025-01-01 | PHASE3 |
| NCT05939180 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2024-04-01 | PHASE2; PHASE3 |
| NCT06158100 | TERMINATED | Acute Myeloid Leukemia |
Antonio M Jimenez Jimenez |
2024-12-04 | PHASE1 |
| NCT04188405 | COMPLETED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
M.D. Anderson Cancer Center |
2020-05-17 | PHASE2 |
| NCT07028086 | RECRUITING | Acute Myeloid Leukemia; Myeloid Sarcoma |
Ruijin Hospital |
2025-06-20 | PHASE2 |
| NCT06501196 | RECRUITING | Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Refractory Acute Myeloid Leukemia |
BlossomHill Therapeutics |
2024-06-19 | PHASE1 |
| NCT06481241 | RECRUITING | Philadelphia Chromosome Negative ALL; Acute Lymphoblastic Leukemia, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2024-06-10 | |
| NCT05701215 | COMPLETED | Chronic Myeloid Leukemia |
Thomas Ernst, PD Dr. med. |
2023-08-31 | PHASE2 |
| NCT06394011 | RECRUITING | Intermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2024-02-15 | PHASE2 |
| NCT05673057 | ACTIVE_NOT_RECRUITING | Leukemia; Myeloid; Acute; Newly Diagnosed |
Molecular Partners AG |
2022-12-29 | PHASE1; PHASE2 |
| NCT04550442 | TERMINATED | Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2020-09-04 | PHASE1; PHASE2 |
| NCT05356169 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2022-05-19 | PHASE2; PHASE3 |
| NCT04739813 | ACTIVE_NOT_RECRUITING | Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma |
National Cancer Institute (NCI) |
2021-07-09 | PHASE1 |
| NCT03613532 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML); MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable); Hematopoietic Stem Cell Transplant |
Jacqueline Garcia, MD |
2018-10-24 | PHASE1 |
| NCT03808610 | TERMINATED | Recurrent B Acute Lymphoblastic Leukemia; Recurrent T Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory T Acute Lymphoblastic Leukemia |
M.D. Anderson Cancer Center |
2019-04-03 | PHASE1; PHASE2 |
| NCT05478512 | ACTIVE_NOT_RECRUITING | High Risk CLL; Chronic Lymphocytic Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2023-07-21 | PHASE2 |
| NCT05768711 | ACTIVE_NOT_RECRUITING | Chronic Myeloid Leukemia |
Groupe Francophone des Myelodysplasies |
2023-10-04 | PHASE2 |
| NCT07007949 | RECRUITING | Acute Myeloid Leukemia; IDH1 Gene Mutation; Ivosidenib |
The First Affiliated Hospital of Soochow University |
2025-06-01 | PHASE2 |
| NCT06115135 | RECRUITING | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Oncotherapeutics |
2024-06-20 | PHASE2 |
| NCT06393985 | RECRUITING | B-cell Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
2024-04-25 | PHASE2 |
| NCT05268003 | TERMINATED | Acute Lymphoblastic Leukemia; Leukemia |
M.D. Anderson Cancer Center |
2022-06-07 | PHASE2 |
| NCT02942290 | COMPLETED | Myelodysplastic Syndromes (MDS) |
AbbVie |
2017-01-12 | PHASE1 |
| NCT04278768 | SUSPENDED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome |
Curis, Inc. |
2020-07-06 | PHASE1; PHASE2 |
| NCT06387420 | NOT_YET_RECRUITING | ACUTE MYELOID LEUKEMIA; AML |
Akeso |
2024-04-29 | PHASE1; PHASE2 |
| NCT06361329 | RECRUITING | ETP-ALL |
First Affiliated Hospital of Zhejiang University |
2024-04-03 | PHASE3 |
| NCT05005299 | UNKNOWN | Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute, L1; Leukemia, Lymphoblastic, Acute, L2; Myelodysplastic Syndromes; Non-hodgkin Lymphoma; Plasma Cell Myeloma |
Melbourne Health |
2022-06-08 | PHASE1 |
| NCT03557619 | UNKNOWN | Hematologic Malignancies |
AbbVie |
2019-07-30 | PHASE1 |
| NCT03404193 | TERMINATED | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myelomonocytic Leukemia; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Refractory Acute Myeloid Leukemia; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia |
M.D. Anderson Cancer Center |
2018-01-18 | PHASE2 |
| NCT05901974 | RECRUITING | Acute Leukemia of Ambiguous Lineage |
Sheng-Li Xue, MD |
2023-07-01 | PHASE2 |
| NCT05668026 | RECRUITING | HIV-1-infection |
University of Aarhus |
2024-04-01 | PHASE1; PHASE2 |
| NCT05144243 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
AbbVie |
2022-01-06 | PHASE4 |
| NCT07039877 | RECRUITING | Acute Lymphobkastic Leukemia; Acute Lymphoblastic Leukaemia Recurrent; Philadelphia Chromosome Negative ALL |
Hospital Universitario Dr. Jose E. Gonzalez |
2025-01-02 | PHASE2 |
| NCT05618366 | TERMINATED | Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma; Follicular Lymphoma |
Weill Medical College of Cornell University |
2023-06-07 | PHASE1 |
| NCT05870995 | RECRUITING | Refractory Leukemia |
Shanghai Jiao Tong University School of Medicine |
2023-02-01 | PHASE2 |
| NCT06191263 | RECRUITING | Acute Myeloid Leukemia |
Ryvu Therapeutics SA |
2024-01-05 | PHASE2 |
| NCT05807932 | RECRUITING | Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia |
Heinrich-Heine University, Duesseldorf |
2023-06-26 | PHASE1; PHASE2 |
| NCT05305859 | RECRUITING | Leukemia, Myeloid, Acute; Relapsed Adult AML; Refractory Leukemia |
The First Affiliated Hospital of Xiamen University |
2022-01-12 | PHASE2 |
| NCT05379166 | ACTIVE_NOT_RECRUITING | Secondary Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome |
Uma Borate |
2022-06-23 | PHASE2 |
| NCT06765928 | NOT_YET_RECRUITING | MDS; AML, Adult |
Ruijin Hospital |
2025-01-01 | PHASE2 |
| NCT04973618 | WITHDRAWN | AML |
Aptevo Therapeutics |
2025-01 | PHASE1 |
| NCT06737523 | RECRUITING | Acute Myeloid Leukemia; Relapse; Refractory AML |
The First Affiliated Hospital of Xiamen University |
2025-03-15 | PHASE1 |
| NCT06450145 | UNKNOWN | Tumour |
Zhejiang Provincial People's Hospital |
2024-05-01 | |
| NCT05528354 | UNKNOWN | Hematopoietic Stem Cell Transplantation; TP53 |
Zhejiang University |
2022-06-02 | EARLY_PHASE1 |
| NCT06746519 | RECRUITING | Acute Myeloid Leukemia |
Chen Suning |
2024-12-25 | PHASE1; PHASE2 |
| NCT04639362 | ACTIVE_NOT_RECRUITING | CLL |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2020-12-29 | PHASE2 |
| NCT05782127 | ACTIVE_NOT_RECRUITING | Untreated Myelodysplastic Syndrome |
Groupe Francophone des Myelodysplasies |
2023-12-06 | PHASE1; PHASE2 |
| NCT06007911 | WITHDRAWN | Relapsed Adult AML; Refractory AML |
Medical College of Wisconsin |
2024-08-31 | PHASE1 |
| NCT04229979 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Sellas Life Sciences Group |
2021-02-08 | PHASE3 |
| NCT03708003 | TERMINATED | Relapsed/Refractory Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Leukemia |
Swiss Cancer Institute |
2019-03-11 | PHASE2 |
| NCT03319901 | ACTIVE_NOT_RECRUITING | Leukemia |
Dana-Farber Cancer Institute |
2017-10-30 | PHASE1; PHASE2 |
| NCT05833438 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
University of Leipzig |
2023-05-17 | PHASE2 |
| NCT05522192 | UNKNOWN | Relapsed or Refractory Acute Myeloid Leukemia |
Hui Zeng |
2022-07-21 | PHASE1; PHASE2 |
| NCT06046313 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
First Affiliated Hospital of Zhejiang University |
2023-10-19 | PHASE2 |
| NCT05105841 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
AbbVie |
2021-11-08 | PHASE2 |
| NCT06742086 | COMPLETED | Healthy Volunteer |
AbbVie |
2024-12-19 | PHASE1 |
| NCT05780879 | TERMINATED | Secondary Acute Myeloid Leukemia |
University of Michigan Rogel Cancer Center |
2024-06-03 | PHASE2 |
| NCT04968015 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
French Innovative Leukemia Organisation |
2022-05-25 | PHASE2 |
| NCT06508489 | TERMINATED | Acute Myeloid Leukemia |
Sanofi |
2024-08-13 | PHASE1; PHASE2 |
| NCT05054465 | UNKNOWN | Acute Lymphoblastic Leukemia |
Israeli Medical Association |
2021-10-01 | PHASE1; PHASE2 |
| NCT06697327 | ENROLLING_BY_INVITATION | Leukemia, Myeloid, Acute; Acute Myeloid Leukemia |
Anhui Medical University |
2025-02-01 | |
| NCT05503355 | UNKNOWN | AML, Adult |
BioSight Ltd. |
2022-08-17 | PHASE1; PHASE2 |
| NCT06544109 | ENROLLING_BY_INVITATION | Acute Promyelocytic Leukemia |
The First Affiliated Hospital of Soochow University |
2023-08-01 | PHASE2; PHASE3 |
| NCT02416388 | RECRUITING | Acute Myeloid Leukemia (AML) |
University Hospital, Angers |
2015-01 | PHASE2; PHASE3 |
| NCT06070948 | WITHDRAWN | Healthy Volunteers |
AbbVie |
2023-10-05 | PHASE1 |
| NCT03504644 | ACTIVE_NOT_RECRUITING | Recurrent Adult Lymphoblastic Lymphoma; Recurrent B Acute Lymphoblastic Leukemia; Recurrent B Lymphoblastic Lymphoma; Recurrent T Acute Lymphoblastic Leukemia; Recurrent T Lymphoblastic Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B Lymphoblastic Lymphoma; Refractory T Acute Lymphoblastic Leukemia; Refractory T Lymphoblastic Lymphoma |
ECOG-ACRIN Cancer Research Group |
2018-08-13 | PHASE1; PHASE2 |
| NCT03455504 | COMPLETED | Acute Myeloid Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2018-10-26 | PHASE2 |
| NCT05546060 | UNKNOWN | Hemophagocytic Lymphohistiocytosis |
Beijing Friendship Hospital |
2022-07-01 | PHASE1 |
| NCT05665530 | COMPLETED | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); Mantle Cell Lymphoma (MCL); Richter's Syndrome; T-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Marginal Zone Lymphoma; Myeloid Malignancies; Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia (CMML); Myelodysplastic Syndrome (MDS); MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome |
Prelude Therapeutics |
2023-09-12 | PHASE1 |
| NCT04843904 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Dana-Farber Cancer Institute |
2021-04-14 | PHASE1 |
| NCT06434662 | UNKNOWN | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy |
First Affiliated Hospital of Zhejiang University |
2024-02-29 | PHASE2 |
| NCT06763666 | NOT_YET_RECRUITING | Relapsed/Refractory AML |
Nanfang Hospital, Southern Medical University |
2025-02 | PHASE4 |
| NCT05909293 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital with Nanjing Medical University |
2023-04-12 | |
| NCT04802590 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
The Lymphoma Academic Research Organisation |
2022-01-24 | PHASE2 |
| NCT05025423 | TERMINATED | Mantle Cell Lymphoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2022-06-21 | PHASE2 |
| NCT04905810 | RECRUITING | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia |
Brian Jonas |
2022-02-09 | PHASE2 |
| NCT06324994 | NOT_YET_RECRUITING | Mantle Cell Lymphoma |
Dalian Medical University |
2024-05-01 | PHASE2 |
| NCT04937166 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia |
Kahr Medical |
2022-01-13 | PHASE1 |
| NCT06449482 | TERMINATED | Acute Myeloid Leukemia, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2023-05-05 | PHASE1; PHASE2 |
| NCT05736965 | RECRUITING | AML, Adult |
Shanghai Tong Ren Hospital |
2023-02-20 | PHASE2 |
| NCT04435691 | TERMINATED | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2020-07-28 | PHASE1; PHASE2 |
| NCT05736978 | RECRUITING | AML; MRD |
Shanghai Tong Ren Hospital |
2023-03-31 | PHASE2 |
| NCT06150040 | TERMINATED | Acute Myeloid Leukemia Refractory |
Centre Leon Berard |
2024-09-11 | PHASE1; PHASE2 |
| NCT03466294 | COMPLETED | Acute Myeloid Leukemia |
University of Colorado, Denver |
2018-05-15 | PHASE2 |
| NCT03740529 | COMPLETED | Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; B-cell Lymphoma; Small Lymphocytic Lymphoma |
Loxo Oncology, Inc. |
2019-03-15 | PHASE1; PHASE2 |
| NCT05823714 | UNKNOWN | Allogeneic Hematopoietic Stem Cell Transplantation; Acute Myeloid Leukemia; Myelodysplastic Syndrome |
The First Affiliated Hospital of Soochow University |
2022-01-20 | PHASE2 |
| NCT04553692 | TERMINATED | Solid Tumor; Colorectal Cancer; Non Hodgkin Lymphoma; Sarcoma; Chondrosarcoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia |
IGM Biosciences, Inc. |
2020-09-23 | PHASE1 |
| NCT05809167 | UNKNOWN | Allogeneic Hematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
2022-01-20 | PHASE2 |
| NCT04867928 | UNKNOWN | Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2022-03-01 | PHASE2 |
| NCT05918198 | UNKNOWN | Acute Myeloid Leukemia |
Peking University People's Hospital |
2023-02-01 | PHASE2 |
| NCT04758975 | RECRUITING | Chronic Lymphocytic Leukemia (CLL) |
Paolo Ghia |
2022-09-19 | PHASE2 |
| NCT03732703 | COMPLETED | Relapsed Refractory Multiple Myeloma |
Multiple Myeloma Research Consortium |
2019-04-01 | PHASE1; PHASE2 |
| NCT05149378 | COMPLETED | Acute T-Lymphocytic Leukemia |
The First Affiliated Hospital of Soochow University |
2021-11-01 | PHASE2 |
| NCT05662956 | COMPLETED | Acute Myeloid Leukemia |
Hematology department of the 920th hospital |
2022-12-01 | PHASE2 |
| NCT06087419 | UNKNOWN | Acute Lymphoblastic Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-10-30 | PHASE1; PHASE2 |
| NCT02401503 | COMPLETED | Chronic Lymphocytic Leucemia |
German CLL Study Group |
2015-05-06 | PHASE2 |
| NCT05506332 | RECRUITING | Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory |
University Hospital, Antwerp |
2022-07-15 | PHASE1 |
| NCT04687761 | COMPLETED | Leukemia, Myeloid, Acute; De Novo; Age More 60yr |
PETHEMA Foundation |
2020-11-04 | PHASE1; PHASE2 |
| NCT05190549 | COMPLETED | Acute Leukemia, Relapsed; Acute Leukemia Refractory |
The First Affiliated Hospital of Soochow University |
2021-10-01 | PHASE2 |
| NCT06073730 | UNKNOWN | Elderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax; Decitabine |
The Second Affiliated Hospital of Kunming Medical University |
2023-11-01 | PHASE3 |
| NCT04150029 | TERMINATED | Acute Myeloid Leukemia |
Novartis Pharmaceuticals |
2020-09-01 | PHASE2 |
| NCT04763928 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2021-12-03 | PHASE2 |
| NCT06030089 | COMPLETED | Acute Myeloid Leukemia |
Centre Hospitalier Universitaire de Nice |
2024-02-26 | |
| NCT04285268 | WITHDRAWN | High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements |
Rutgers, The State University of New Jersey |
2020-05-06 | PHASE2 |
| NCT05654194 | COMPLETED | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2022-10-31 | PHASE3 |
| NCT04874194 | TERMINATED | Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Biphenotypic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2021-12-17 | PHASE1; PHASE2 |
| NCT06078306 | UNKNOWN | B Acute Lymphoblastic Leukemia; Ph-Negative ALL; High Risk Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
2024-04-20 | PHASE2 |
| NCT03955783 | COMPLETED | Diffuse Large B-cell Lymphoma; Acute Myeloid Leukemia; Non-Hodgkin's Lymphoma |
Sanjay Mohan |
2019-06-21 | PHASE1 |
| NCT04905407 | TERMINATED | Acute Myeloid Leukemia |
Syros Pharmaceuticals |
2021-08-26 | PHASE2 |
| NCT05464836 | TERMINATED | Leukemia, Lymphoblastic; Leukemia |
M.D. Anderson Cancer Center |
2023-04-06 | PHASE2 |
| NCT03422393 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Michael Choi |
2018-05-01 | PHASE1 |
| NCT05168202 | TERMINATED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes |
Bristol-Myers Squibb |
2022-01-19 | PHASE1 |
| NCT05371054 | COMPLETED | Lymphoma; Non-Hodgkin Lymphoma; NHL; Hematologic Malignancies; Lymphoid Malignancies |
National Cancer Institute (NCI) |
2023-04-05 | PHASE1; PHASE2 |
| NCT04512105 | COMPLETED | Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; AML, Adult; CLL; CLL, Relapsed; CLL, Refractory |
University of California, Irvine |
2020-12-02 | PHASE1 |
| NCT03530683 | TERMINATED | Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma |
Pfizer |
2018-05-14 | PHASE1 |
| NCT05211336 | ACTIVE_NOT_RECRUITING | Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS); Aggressive B-cell Lymphoma With Secondary Involvement of the CNS |
National Cancer Institute (NCI) |
2022-04-19 | PHASE1 |
| NCT05448599 | UNKNOWN | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
Mabwell (Shanghai) Bioscience Co., Ltd. |
2022-07-08 | PHASE1; PHASE2 |
| NCT06068621 | COMPLETED | Acute Myeloid Leukemia |
Chinese PLA General Hospital |
2023-03-01 | PHASE2 |
| NCT04790903 | TERMINATED | Lymphoma, Large B-Cell, Diffuse |
Hoffmann-La Roche |
2021-07-02 | PHASE1 |
| NCT04447716 | ACTIVE_NOT_RECRUITING | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Marginal Zone Lymphoma |
Thomas Jefferson University |
2020-10-16 | PHASE1 |
| NCT04029688 | TERMINATED | Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Neuroblastoma; Solid Tumors |
Hoffmann-La Roche |
2020-01-27 | PHASE1; PHASE2 |
| NCT05564650 | COMPLETED | Myelodysplastic Syndrome; Recurrent Myelodysplastic Syndrome; Refractory Myelodysplastic Syndrome |
Thomas Jefferson University |
2023-01-12 | PHASE1 |
| NCT06382168 | Not yet recruiting | Leukemia Myeloid Acute |
Delta-Fly Pharma Inc. |
2024-05-31 | Phase 1|Phase 2 |
| NCT05455294 | ACTIVE_NOT_RECRUITING | Myeloid Malignancy; Myelodysplastic Syndromes; Myelofibrosis; Acute Myeloid Leukemia; Myeloproliferative Neoplasm |
Jacqueline Garcia, MD |
2022-07-18 | PHASE1 |
| NCT05433532 | COMPLETED | Philadelphia Chromosome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Mixed Phenotype Acute Leukemia |
The First Affiliated Hospital of Soochow University |
2022-05-01 | PHASE2 |
| NCT03580928 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL) |
Dana-Farber Cancer Institute |
2018-08-07 | PHASE2 |
| NCT05893472 | UNKNOWN | Acute Myeloid Leukemia; Venetoclax |
ZePing Zhou |
2023-04-01 | PHASE1; PHASE2 |
| NCT06263387 | Not yet recruiting | AML Adult |
French Innovative Leukemia Organisation|Acute Leukemia French Association |
2024-04-29 | -- |
| NCT04659044 | TERMINATED | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma |
Academic and Community Cancer Research United |
2021-04-01 | PHASE2 |
| NCT04778397 | TERMINATED | Acute Myeloid Leukemia |
Gilead Sciences |
2021-07-01 | PHASE3 |
| NCT05976217 | COMPLETED | Idiopathic Pulmonary Fibrosis |
University of Alabama at Birmingham |
2023-10-01 | EARLY_PHASE1 |
| NCT03226418 | COMPLETED | Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia |
University of Nebraska |
2017-07-07 | PHASE2 |
| NCT04778410 | TERMINATED | Myeloid Malignancies |
Gilead Sciences |
2021-06-28 | PHASE2 |
| NCT02950051 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2016-12-13 | PHASE3 |
| NCT04267081 | COMPLETED | Acute Myeloid Leukemia |
Helsinki University Central Hospital |
2020-02-12 | PHASE2 |
| NCT05177731 | ACTIVE_NOT_RECRUITING | AML, Adult; Chemotherapy Effect |
Chen Suning |
2022-03-01 | PHASE3 |
| NCT06109064 | UNKNOWN | Myelodysplastic Syndromes |
Anhui Provincial Hospital |
2023-10-27 | PHASE2 |
| NCT06105658 | UNKNOWN | Acute Myelocytic Leukemia |
Anhui Provincial Hospital |
2023-10 | PHASE2 |
| NCT05807347 | UNKNOWN | Refractory/Relapse Acute Myeloid Leukemia |
Hematology department of the 920th hospital |
2023-02-01 | PHASE2 |
| NCT04926285 | COMPLETED | Relapsed or Refractory Hematologic Malignancies |
University of Illinois at Chicago |
2022-06-21 | PHASE1 |
| NCT03063944 | COMPLETED | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-03-17 | PHASE1 |
| NCT04887857 | COMPLETED | Leukemia, Myeloid, Acute |
Celgene |
2021-12-01 | PHASE1 |
| NCT04904237 | UNKNOWN | Refractory Acute Myeloid Leukemia |
Shanghai Jiao Tong University School of Medicine |
2021-01-01 | PHASE2 |
| NCT04655391 | WITHDRAWN | Recurrent Acute Myeloid Leukemia |
City of Hope Medical Center |
2022-06-25 | PHASE1 |
| NCT03713580 | COMPLETED | Non-hodgkin Lymphoma |
Case Comprehensive Cancer Center |
2019-03-12 | PHASE1 |
| NCT03932318 | WITHDRAWN | Acute Myeloid Leukemia; Relapsed Adult AML |
Actinium Pharmaceuticals |
2023-03 | PHASE1; PHASE2 |
| NCT03492125 | TERMINATED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Aggressive Lymphoma |
MingSight Pharmaceuticals, Inc |
2018-05-25 | PHASE1; PHASE2 |
| NCT04336982 | TERMINATED | Leukemia, Myeloid, Acute |
Celgene |
2020-08-05 | PHASE1 |
| NCT06085638 | WITHDRAWN | Chronic Myelomonocytic Leukemia |
M.D. Anderson Cancer Center |
2023-09-14 | PHASE1; PHASE2 |
| NCT04070768 | COMPLETED | Acute Myeloid Leukemia |
John Quigley |
2019-09-06 | PHASE1 |
| NCT04898894 | ACTIVE_NOT_RECRUITING | Acute Leukemia of Ambiguous Lineage in Relapse; Acute Myeloid Leukemia, in Relapse; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2021-11-15 | PHASE1 |
| NCT05262465 | UNKNOWN | Adult Acute Myeloid Leukemia |
guomei |
2020-07-01 | |
| NCT04284787 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2021-02-16 | PHASE2 |
| NCT02956382 | COMPLETED | Refractory Follicular Lymphoma; Relapsed Follicular Lymphoma |
Georgetown University |
2017-03-01 | PHASE1; PHASE2 |
| NCT04812548 | TERMINATED | Myelodysplastic Syndrome (MDS) |
Novartis Pharmaceuticals |
2021-05-31 | PHASE2 |
| NCT05362942 | UNKNOWN | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Minimal Residual Disease |
Beijing 302 Hospital |
2022-05-01 | PHASE2 |
| NCT03236857 | COMPLETED | Malignancies; Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Non-Hodgkin's Lymphoma; Neuroblastoma |
AbbVie |
2017-11-08 | PHASE1 |
| NCT02966782 | COMPLETED | Myelodysplastic Syndromes (MDS) |
AbbVie |
2017-03-07 | PHASE1 |
| NCT05471700 | COMPLETED | Leukemia, Myeloid, Acute |
Zhujiang Hospital |
2022-09-01 | |
| NCT04010968 | COMPLETED | Intermediate Risk Chronic Lymphocytic Leukemia; Fit Patients; Risk-Adapted and MRD-Driven Strategy |
French Innovative Leukemia Organisation |
2019-09-27 | PHASE2 |
| NCT05209308 | WITHDRAWN | CLL |
MEI Pharma, Inc. |
2022-11-22 | PHASE2 |
| NCT05361057 | TERMINATED | Acute Myeloid Leukemia; Measurable Disease |
Institute of Hematology & Blood Diseases Hospital, China |
2022-06-29 | PHASE2 |
| NCT04487106 | COMPLETED | Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2020-07-21 | PHASE2 |
| NCT04476199 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Gruppo Italiano Trapianto di Midollo Osseo |
2019-12-09 | PHASE2 |
| NCT05457361 | UNKNOWN | Venetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine |
Nanfang Hospital, Southern Medical University |
2022-03-01 | PHASE3 |
| NCT03801525 | TERMINATED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
TG Therapeutics, Inc. |
2019-05-16 | PHASE2; PHASE3 |
| NCT03484520 | TERMINATED | Cancer - Acute Myeloid Leukemia |
AbbVie |
2018-07-23 | PHASE1 |
| NCT04017546 | COMPLETED | AML; MDS |
Cyclacel Pharmaceuticals, Inc. |
2019-08-02 | PHASE1 |
| NCT03672695 | COMPLETED | Acute Myeloid Leukaemia |
Institut de Recherches Internationales Servier |
2018-11-28 | PHASE1 |
| NCT03834688 | COMPLETED | Mantle Cell Lymphoma |
PrECOG, LLC. |
2020-01-13 | PHASE2 |
| NCT05084027 | UNKNOWN | Hematologic Malignancy; Older Patients; Allogeneic Hematopoietic Stem Cell Transplantation |
First Affiliated Hospital of Zhejiang University |
2021-10-07 | PHASE2 |
| NCT04266795 | COMPLETED | Acute Myeloid Leukemia (AML) |
Takeda |
2020-10-13 | PHASE2 |
| NCT04810598 | COMPLETED | Renal Impairment; Renal Disease |
AbbVie |
2021-07-08 | PHASE1 |
| NCT05282719 | UNKNOWN | Myelodysplastic/Myeloproliferative Neoplasms; Adult |
The First Affiliated Hospital of Soochow University |
2022-04 | PHASE2 |
| NCT03751436 | COMPLETED | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
Roswell Park Cancer Institute |
2019-08-02 | PHASE1 |
| NCT01682616 | COMPLETED | Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia |
AbbVie |
2012-07-25 | PHASE1 |
| NCT02203773 | TERMINATED | Acute Myelogenous Leukemia; Myelogenous Leukemia; Treatment Naive AML |
AbbVie |
2014-10-06 | PHASE1 |
| NCT04273139 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia; MYD88 Gene Mutation |
Dana-Farber Cancer Institute |
2020-07-09 | PHASE2 |
| NCT03379051 | TERMINATED | Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma |
TG Therapeutics, Inc. |
2018-03-27 | PHASE1; PHASE2 |
| NCT04038437 | COMPLETED | Acute Myeloid Leukemia |
Jazz Pharmaceuticals |
2019-10-15 | PHASE1 |
| NCT03000257 | COMPLETED | Advanced Solid Tumors |
AbbVie |
2016-12-14 | PHASE1 |
| NCT03941964 | COMPLETED | Acute Myeloid Leukemia (AML); Cancer |
AbbVie |
2019-08-15 | PHASE3 |
| NCT04748848 | TERMINATED | Leukemia, Myeloid |
Celgene |
2021-10-14 | PHASE1 |
| NCT04477486 | COMPLETED | Mantle Cell Lymphoma (MCL) |
AbbVie |
2020-09-23 | PHASE2 |
| NCT04075747 | COMPLETED | Acute Myeloid Leukemia |
Jazz Pharmaceuticals |
2019-12-02 | PHASE1 |
| NCT03390296 | COMPLETED | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2017-12-27 | PHASE1; PHASE2 |
| NCT04214860 | COMPLETED | Myeloid Malignancy |
Aprea Therapeutics |
2019-12-13 | PHASE1 |
| NCT03485547 | COMPLETED | Blastic Plasmacytoid Dendritic Cell Neoplasm |
Dana-Farber Cancer Institute |
2018-08-23 | PHASE1 |
| NCT03766763 | ACTIVE_NOT_RECRUITING | Chronic Lymphoid Leukemia |
French Innovative Leukemia Organisation |
2019-05-22 | PHASE2 |
| NCT02758665 | COMPLETED | Leukemia, Lymphocytic, Chronic |
University of Ulm |
2016-09 | PHASE2 |
| NCT03856112 | WITHDRAWN | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma; t(11;14) Negative |
National Cancer Institute (NCI) |
2019-06-21 | PHASE1; PHASE2 |
| NCT02980731 | COMPLETED | Chronic Lymphocytic Leukemia (CLL) |
AbbVie |
2016-12-13 | PHASE3 |
| NCT02427451 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia |
Kerry Rogers |
2015-08-03 | PHASE1; PHASE2 |
| NCT02141282 | COMPLETED | Chronic Lymphocytic Leukemia |
AbbVie |
2014-09-10 | PHASE2 |
| NCT03399539 | COMPLETED | Recurrent Plasma Cell Myeloma; T(11;14) |
Mayo Clinic |
2018-05-02 | PHASE1 |
| NCT02993523 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
AbbVie |
2017-02-02 | PHASE3 |
| NCT01794520 | COMPLETED | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2012-10-10 | PHASE1; PHASE2 |
| NCT04073147 | TERMINATED | Primary CNS Lymphoma |
Klinikum Stuttgart |
2020-05-12 | PHASE1 |
| NCT03873493 | COMPLETED | Leukemia; T-cell Prolymphocytic Leukemia (T-PLL); Cancer |
AbbVie |
2020-01-14 | PHASE2 |
| NCT04146038 | COMPLETED | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia |
Rutgers, The State University of New Jersey |
2020-10-26 | PHASE2 |
| NCT02987400 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2017-01-04 | PHASE2 |
| NCT03639324 | WITHDRAWN | Chronic Lymphocytic Leukemia; CLL; Relapsed CLL; Refractory Chronic Lymphocytic Leukemia; Relapsed Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; SLL; Relapsed Small Lymphocytic Lymphoma; Refractory Small Lymphocytic Lymphoma |
Virginia Commonwealth University |
2020-10-02 | PHASE1 |
| NCT03406156 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
AbbVie |
2018-08-10 | PHASE3 |
| NCT03218683 | TERMINATED | Relapsed or Refractory Acute Myeloid Leukemia (AML) |
AstraZeneca |
2017-08-02 | PHASE1 |
| NCT03583424 | COMPLETED | Hematopoietic Cell Transplantation Recipient; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Transformed Indolent Non-Hodgkin Lymphoma |
Ohio State University Comprehensive Cancer Center |
2018-09-10 | PHASE1; PHASE2 |
| NCT03113643 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm |
Dana-Farber Cancer Institute |
2017-06-26 | PHASE1 |
| NCT04419389 | TERMINATED | Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma |
Aprea Therapeutics |
2021-03-02 | PHASE1; PHASE2 |
| NCT02296918 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Prolymphocytic Leukemia |
Acerta Pharma BV |
2014-12-22 | PHASE1 |
| NCT02287233 | COMPLETED | Acute Myelogenous Leukemia; AML |
AbbVie |
2014-12-31 | PHASE1; PHASE2 |
| NCT03943342 | WITHDRAWN | Chronic Lymphocytic Leukemia; Loss of Chromosome 17p |
Kerry Rogers |
2020-03-11 | PHASE2 |
| NCT03226301 | UNKNOWN | Chronic Lymphocytic Leukemia in Relapse; Chronic Lymphocytic Leukemia in Remission |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2017-06-23 | PHASE2 |
| NCT03336333 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
BeiGene |
2017-10-31 | PHASE3 |
| NCT03113422 | COMPLETED | Follicular Lymphoma; Non-Hodgkin's Lymphoma Follicular; Non-Hodgkin's Lymphoma, Adult High Grade |
PrECOG, LLC. |
2017-12-27 | PHASE2 |
| NCT02419560 | COMPLETED | Lymphoma, Mantle-Cell; Recurrent Lymphoma, Mantle-Cell |
Craig Portell, MD |
2015-04 | PHASE1 |
| NCT03969420 | TERMINATED | Acute Myeloid Leukemia (AML) |
Sumitomo Pharma America, Inc. |
2020-01-15 | PHASE2 |
| NCT04509622 | COMPLETED | Acute Myeloid Leukemia (AML) |
AbbVie |
2020-10-05 | PHASE3 |
| NCT02755597 | COMPLETED | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2016-07-11 | PHASE3 |
| NCT02265731 | COMPLETED | Non-Hodgkin Lymphoma (NHL); Multiple Myeloma (MM); Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Acute Myeloid Leukemia (AML) |
AbbVie |
2014-09-22 | PHASE1; PHASE2 |
| NCT03462719 | ACTIVE_NOT_RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell |
Janssen Research & Development, LLC |
2018-04-17 | PHASE3 |
| NCT03787264 | COMPLETED | Chronic Lymphoid Leukemia |
German CLL Study Group |
2019-01-14 | PHASE2 |
| NCT04171791 | COMPLETED | CTCL |
Yale University |
2020-01-15 | PHASE1 |
| NCT04298918 | TERMINATED | Breast Cancer |
Hoffmann-La Roche |
2020-09-23 | PHASE1; PHASE2 |
| NCT03755947 | COMPLETED | B-Cell Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis) |
Grupo Cooperativo de Hemopatías Malignas |
2018-12-01 | PHASE2 |
| NCT02471391 | UNKNOWN | Mantle Cell Lymphoma |
Peter MacCallum Cancer Centre, Australia |
2015-07-22 | PHASE2 |
| NCT02910583 | COMPLETED | Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Pharmacyclics LLC. |
2016-09-28 | PHASE2 |
| NCT03181126 | COMPLETED | Acute Lymphoblastic Leukemia (ALL); Lymphoblastic Lymphoma |
AbbVie |
2017-11-27 | PHASE1 |
| NCT03136497 | TERMINATED | Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
Hackensack Meridian Health |
2017-09-05 | PHASE1 |
| NCT01889186 | COMPLETED | Chronic Lymphocytic Leukemia; 17p Deletion; Cancer of the Blood and Bone Marrow |
AbbVie |
2013-06-27 | PHASE2 |
| NCT03194932 | COMPLETED | Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2017-07-11 | PHASE1 |
| NCT04493099 | WITHDRAWN | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2020-10 | PHASE1; PHASE2 |
| NCT01742988 | COMPLETED | Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Relapsed and/or Refractory Lymphoma; Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL); Refractory Diffuse Large B-Cell Lymphoma (DLBCL); Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL); Double-hit Lymphoma (DHL); Triple-hit Lymphoma (THL); Double-expressor Lymphoma (DEL); High-grade B-cell Lymphoma (HGBL) |
Curis, Inc. |
2012-12 | PHASE1 |
| NCT04274933 | TERMINATED | Breast Cancer; Cancer |
AbbVie |
2020-05-21 | PHASE1 |
| NCT03584009 | TERMINATED | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-09-06 | PHASE2 |
| NCT01594229 | COMPLETED | Non-Hodgkin's Lymphoma |
AbbVie |
2012-05-21 | PHASE1 |
| NCT01211457 | UNKNOWN | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Cyclacel Pharmaceuticals, Inc. |
2010-06-17 | PHASE1; PHASE2 |
| NCT03567616 | TERMINATED | Multiple Myeloma |
AbbVie |
2018-10-18 | PHASE2 |
| NCT03701321 | WITHDRAWN | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
National Cancer Institute (NCI) |
2019-01-25 | PHASE1; PHASE2 |
| NCT01328626 | COMPLETED | Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma |
AbbVie |
2011-05-23 | PHASE1 |
| NCT03552692 | TERMINATED | T-Cell Lymphoma Relapsed; T-Cell Lymphoma Refractory |
Fondazione Italiana Linfomi - ETS |
2018-09-25 | PHASE2 |
| NCT03884972 | WITHDRAWN | Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2019-06-18 | PHASE1 |
| NCT02677324 | COMPLETED | Waldenstrom Macroglobulinemia |
Dana-Farber Cancer Institute |
2016-05-09 | PHASE2 |
| NCT01969695 | COMPLETED | Non-Hodgkin's Lymphoma |
AbbVie |
2013-12-20 | PHASE1 |
| NCT03000660 | TERMINATED | AL Amyloidosis |
Tufts Medical Center |
2017-01 | PHASE1 |
| NCT03276468 | COMPLETED | Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Marginal Zone Lymphoma; Mucosa Associated Lymphoid Tissue |
The Lymphoma Academic Research Organisation |
2018-02-12 | PHASE2 |
| NCT03785184 | WITHDRAWN | Multiple Myeloma |
AbbVie |
2019-04-29 | PHASE2 |
| NCT01794507 | COMPLETED | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2012-11-19 | PHASE1 |
| NCT02391480 | COMPLETED | Cancer; Breast Cancer; Non-Small Cell Lung Cancer; Acute Myeloid Leukemia (AML); Multiple Myeloma; Prostate Cancer; Small Cell Lung Cancer; Non-Hodgkins Lymphoma |
AbbVie |
2015-04-14 | PHASE1 |
| NCT03255096 | COMPLETED | Diffuse Large B-cell Lymphoma; High-Grade B-cell Lymphoma |
Hoffmann-La Roche |
2017-08-28 | PHASE1 |
| NCT02756611 | COMPLETED | Chronic Lymphocytic Leukemia |
AbbVie |
2016-06-22 | PHASE3 |
| NCT02558816 | COMPLETED | Mantle Cell Lymphoma |
Nantes University Hospital |
2015-10-14 | PHASE1; PHASE2 |
| NCT02639910 | COMPLETED | Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
MorphoSys AG |
2016-11 | PHASE2 |
| NCT02242942 | COMPLETED | Lymphocytic Leukemia, Chronic |
Hoffmann-La Roche |
2014-12-31 | PHASE3 |
| NCT01671904 | COMPLETED | Chronic Lymphocytic Leukemia |
Genentech, Inc. |
2014-01-13 | PHASE1 |
| NCT03343678 | WITHDRAWN | Leukemia, Lymphocytic, Chronic, B-Cell |
Boehringer Ingelheim |
2018-01-17 | PHASE1 |
| NCT01685892 | COMPLETED | Lymphocytic Leukemia, Chronic |
Genentech, Inc. |
2012-11-29 | PHASE1 |
| NCT02055820 | COMPLETED | Lymphoma, Non-Hodgkin |
Hoffmann-La Roche |
2013-11-17 | PHASE1; PHASE2 |
| NCT02005471 | COMPLETED | Chronic Lymphocytic Leukemia |
Hoffmann-La Roche |
2014-03-17 | PHASE3 |
| NCT02187861 | COMPLETED | Follicular Lymphoma |
Hoffmann-La Roche |
2014-12-01 | PHASE2 |
| NCT01686555 | COMPLETED | Lupus Erythematosus |
AbbVie (prior sponsor, Abbott) |
2012-11 | PHASE1 |
| NCT01994837 | COMPLETED | Acute Myelogenous Leukemia; AML; Acute Myeloid Leukemia |
AbbVie |
2013-11 | PHASE2 |
| NCT01969669 | COMPLETED | Non-Hodgkin's Lymphoma |
AbbVie |
2013-12 | PHASE1 |
| NCT02095574 | WITHDRAWN | Relapsed/Refractory Non-Hodgkin's Lymphoma |
AbbVie |
2014-09 | PHASE1 |
| NCT01969682 | WITHDRAWN | Non-Hodgkin's Lymphoma |
AbbVie |
2014-04 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-19)
Check the
ABT-199 (Venetoclax)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Venetoclax (ABT-199) Mechanism of Action: BCL-2 Inhibition in Myeloblast Research
- Venetoclax (ABT-199) Working Concentration | Cell Culture | Treatment
- ABT-199 (Venetoclax) Solubility in DMSO
- ABT-199 (Venetoclax) Stock Solution
- ABT-199 (Venetoclax) Storage
- ABT-199 (Venetoclax) Stability
- Venetoclax (ABT-199) VS Navitoclax (ABT-263) | ABT-737
- ABT-199 (Venetoclax) Molecular Weight
- ABT-199 (Venetoclax) SMILES
- ABT-199 (Venetoclax) CAS Number
- ABT-199 (Venetoclax) Chemical Structure (2D and 3D)
- Venetoclax (ABT-199) IC50 for Cell-based and Cell-free Assays
- Venetoclax (ABT-199) TargetMol (T2119)? Try a better option.
- Venetoclax (ABT-199) MedChemExpress (HY-15531)? Try a better option.
- Venetoclax (ABT-199) Abcam (ab217298)? Try a better option.
- Venetoclax (ABT-199) Cayman (16233)? Try a better option.
- Venetoclax (ABT-199) Tocris (6960)? Try a better option.
- ABT-199 (Venetoclax) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.